Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs
Fixed-duration treatments differ from continuous therapy in CLL. Venetoclax-based regimens are approved for 12 cycles with obinutuzumab in frontline and 24 cycles with rituximab in relapsed/refractory settings.
Reference News
Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs
Fixed-duration treatments differ from continuous therapy in CLL. Venetoclax-based regimens are approved for 12 cycles with obinutuzumab in frontline and 24 cycles with rituximab in relapsed/refractory settings.